Glycomics Platform


Leveraging the best global talent and technology

Synedgen has established an unrivaled, virtual drug discovery team.

Broad spectrum of expertise

With our highly experienced team of internal and external leaders, we can apply the platform broadly. We leverage in-house research, development and translational expertise with external thought leaders in particular disease areas to intelligently select targets.

Significant government partnerships

Synedgen has won competitive peer-reviewed grants from the following agencies:

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Institute of Dental and Craniofacial Research (NIDCR)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Cancer Institute (NCI)
  • National Heart, Lung and Blood Institute (NHLB)
  • U.S. Army Medical Research and Materiel Command (MRMC)
  • Defense Advanced Research Projects Agency (DARPA)

This non-dilutive capital has enabled development of our technology platform, the related IP and our extensive pipeline.

World expert academic partners

Synedgen works with national and international leaders in specific fields, wherein we can apply our technology platform.

John Englehardt, PhD

Dr. John Englehardt is the Director of the Center for Gene Therapy at the University of Iowa, and is most widely recognized for his contributions to the creation of new animal models for the study of cystic fibrosis. In the 1990s he developed the human tracheal xenograft models that allow for the study of humanized airways on denuded rat tracheal scaffolds. These studies led to over 20 publications evaluating cystic fibrosis pathophysiology and gene therapy. He was instrumental in identifying submucosal glands as key sites of CFTR function in the lung. Dr. Engelhardt conceived of and created a ferret model of cystic fibrosis as well as a CFTR knockout model. He also has a long-standing interest in redox-dependent signaling of pro-inflammatory receptors.

Drucy Borowitz, MD

Dr. Drucy Borowitz is an internationally recognized expert in nutrition and the involvement of the intestine and lung in cystic fibrosis, and a leading researcher of enzyme replacement therapy to correct digestive abnormalities in cystic fibrosis patients. She has pioneered research using novel agents and dietary supplements to address the challenges her patients face with colonopathy and pulmonary function. Dr. Borowitz played a key role in recruiting and observing patients for the development of Kalydeco, the first CFTR protein correcting drug. She is the recipient of the 2015 Stockton Kimball Award for outstanding scientific achievement and service.

Steve Sonis, DMD, DMSc

Dr. Steve Sonis is a senior surgeon at Brigham and Women’s Hospital specializing in oral medicine, Chief, Division of Oral Medicine, Surgery, Dana-Farber Cancer Institute, and is a Clinical Professor of Oral Medicine at the Harvard School of Dental Medicine. Dr. Sonis is actively involved in translational and clinical research in supportive cancer care, radiation-injury, and genomics. His research focuses on understanding the fundamental biological processes that lead to damage and inflammation at mucosal surfaces. His specific expertise is mucosal toxicities following cancer treatment regimens, identifying the genetic factors that predispose patients to toxicities, and developing and testing effective toxicity interventions. His research group has identified the biological pathways that are associated with injuries of the GI tract, skin, and lung, cancer regimen-related cognitive dysfunction and cancer-related fatigue.

Charles L. Hofacre, DVM, MAM, PhD

Dr. Charles Hofacre is the Director of Clinical Services, Poultry Diagnostic and Research Center, College of Veterinary Medicine at the University of Georgia. He is a recognized expert in the fields of clinical avian medicine, foodborne pathogens associated with poultry, and antibiotic resistant bacteria. He is an internationally recognized thought leader in the effects of antibiotic use in animals, the emergence of bacterial resistance, and the role of commensal bacterial in the health of the gastrointestinal tract. Dr. Hofacre serves on numerous national and international boards and committees, educating on antibacterial resistance and pathogen control advice.